 |
인쇄하기
취소
|
Sanofi-Aventis Korea announces availability of oral Amavan
Sanofi-Aventis Korea announces on May 9 the availability of Amavan (rosiglitazone maleate and glimepiride), a new fixed-dose combination product for type 2 diabetes.
As an adjunct to diet and exercise, Amavan is indicated to improve blood sugar control in patients with type 2 diabetes who are already treated with a combination of rosiglitazone and sulfonylurea or who are not adequately contr...
As an adjunct to diet and exercise, Amavan is indicated to improve blood sugar control in patients with type 2 diabetes who are already treated with a combination of rosiglitazone and sulfonylurea or who are not adequately contr...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.